news
Roche cancer immunotherapy receives new EU approval
16 January 2024 | By
The subcutaneous injection of the novel cancer immunotherapy Tecentriq® (atezolizumab) could provide a quicker alternative to intravenous infusion, research shows.
List view / Grid view
atezolizumab
news
Clinical trial-first for liver cancer immunotherapy combo
IMbrave050 is the first Phase III study to show a cancer immunotherapy combo reduced risk of disease recurrence for early-stage hepatocellular carcinoma.
news
First treatment approval for advanced ASPS
A Phase II trial has led to the FDA approval of atezolizumab for individuals over two years old with advanced alveolar soft part sarcoma.
news
Individualised mRNA vaccine shows promise in pancreatic cancer patients
Phase I study shows that mRNA-based individualised neoantigen specific immunotherapy (iNeST) vaccines can be used to stimulate T cells to recognise neoantigens in pancreatic cancer patients.
news
Neoadjuvant atezolizumab combination meets safety criteria in pleural mesothelioma
Neoadjuvant cisplatin and pemetrexed in combination with atezolizumab met safety criteria in resectable pleural mesothelioma clinical study.
news
NICE fails to recommend pembrolizumab in final draft guidance
The UK NICE has not found pembrolizumab cost-effective for use on the NHS, after a review of evidence collected while the drug was available via the Cancer Drugs Fund.
news
Immunotherapy success for triple-negative breast cancer
A combination of chemotherapy and immunotherapy could soon be used in NHS hospitals for triple-negative breast cancer to extend patient survival...
news
Global urological cancers market to double by 2022, says GBI Research
30 June 2016 | By Victoria White, Digital Content Producer
The urological cancers market will increase from $17.9 billion in 2015 to $35.9 billion by 2022, according to business intelligence provider GBI Research...
news
Tecentriq to dominate the bladder cancer market, says GlobalData
14 June 2016 | By Victoria White, Digital Content Producer
The launch of Roche’s Tecentriq will usher in a dramatic change in the treatment paradigm of bladder cancer, according to an analyst with GlobalData...
news
FDA grants priority review to Roche’s atezolizumab in urothelial carcinoma
15 March 2016 | By Victoria White
The priority review is based on results of the IMvigor 210 study that evaluated the safety and efficacy of atezolizumab in people with locally advanced or metastatic urothelial carcinoma, regardless of PD-L1 expression.
news
Bladder cancer treatment market set to boom, says GlobalData
14 January 2016 | By Victoria White
The company states that the growth will be primarily down to the introduction of Telesta Therapeutics MCNA and Roche’s atezolizumab in 2016 and Bristol-Myers Squibb’s Opdivoin 2017...
news
Roche presents updated results for atezolizumab in mUC
8 January 2016 | By Victoria White
Median overall survival from the updated study results was 11.4 months in people with higher levels of PD-L1 expression, and 7.9 months in the overall study population...
news
Atezolizumab could spur bladder cancer treatment innovation
28 July 2015 | By Victoria White
Atezolizumab is poised to become a major bladder cancer therapy in the race for FDA approval, following its promising performance in recent Phase II trials...
news
Atezolizumab shrank tumours in people with a specific type of bladder cancer in Phase II study
13 July 2015 | By Victoria White
In the Phase II IMvigor 210 study, Roche’s atezolizumab shrank tumours in people with locally advanced or metastatic urothelial bladder cancer (UBC)...
